Physician profile
Dean Park
NPI 1205983004
$1,139.00
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.12 · 2020: $14.14 · 2022: $490 · 2023: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $92.40 | 2022-2023 | Pomalyst |
| Incyte Corporation | $80.93 | 2022-2023 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $75.54 | 2020-2023 | |
| Karyopharm Therapeutics INC. | $69.13 | 2022-2023 | Xpovio |
| G1 Therapeutics, INC. | $65.91 | 2022 | |
| Alexion Pharmaceuticals, INC. | $63.56 | 2022-2023 | Ultomiris |
| Genzyme Corporation | $60.39 | 2022-2023 | |
| Glaxosmithkline, LLC. | $49.52 | 2022 | |
| Mirati Therapeutics, INC. | $48.64 | 2023 | Krazati |
| Morphosys, US INC. | $45.29 | 2022-2023 | Monjuvi |
| Exelixis INC. | $44.27 | 2022-2023 | Cabometyx |
| Amgen INC. | $44.26 | 2022-2023 | Lumakras |
| Alnylam Pharmaceuticals INC. | $27.99 | 2023 | Givlaari |
| Beigene USA, INC. | $27.26 | 2023 | Brukinsa |
| Tersera Therapeutics LLC | $26.19 | 2023 | Xermelo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $25.77 | 2023 | |
| Aveo Pharmaceuticals, INC. | $24.17 | 2023 | Fotivda |
| Seagen INC. | $23.81 | 2022 | |
| Immunogen, INC. | $23.27 | 2023 | Elahere |
| Rigel Pharmaceuticals, INC. | $22.91 | 2023 | Tavalisse, Rezlidhia |
| Recordati_rare_diseases_inc. | $22.80 | 2023 | Sylvant |
| Sanofi-Aventis U.S. LLC | $22.56 | 2022 | |
| Stemline Therapeutics INC. | $22.31 | 2022 | |
| Adc Therapeutics America, INC. | $21.75 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $21.09 | 2022 | |
| Janssen Biotech, INC. | $20.77 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.80 | 2022 | |
| Cti Biopharma Corp. | $18.59 | 2023 | Vonjo |
| Merck Sharp & Dohme LLC | $14.83 | 2019 | |
| Pfizer INC. | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.